BACKGROUND: We sought to identify predictors of asthma development following severe early childhood RSV bronchiolitis. Different definitions of asthma were also compared. METHODS: This longitudinal, observational study (N = 343) followed patients (<2 years old) from a placebo-controlled trial (N = 979) of montelukast after RSV bronchiolitis to identify clinical, demographic, or biochemical predictors of asthma, atopic disorders, and chronic asthma therapy use at 6 years of age (Clinical Trials Registry Number: NCT01140048). Asthma (primary definition) was based on parental identification of wheeze at 6 AND 12 months before 6 years of age; definitions based on physician diagnosis as well as parental identification of wheeze at 6 OR 12 months (to consider seasonal effect) were also assessed. Post-hoc analyses evaluated agreement among asthma diagnosis criteria. RESULTS: Prevalence of asthma (primary definition by parental identification), asthma (physician diagnosis), atopic disorders, and chronic asthma therapy use (parental identification) was 6.1%, 22.4%, 36.2%, and 14.5%, respectively. Predictors for asthma (primary definition) included male gender, a relative with asthma, and RAST positive for dog dander; for physician diagnosis of asthma, high severity score for RSV bronchiolitis, high respiratory rate, and asthma diagnosis before enrollment. Predictors of atopic disorders included allergic rhinitis before enrollment, a relative with asthma, and the plasma biomarkers IL-5, IL-16, and IL-18. Predictors of chronic asthma therapy use included asthma diagnosis before enrollment and geographic region (Europe and Africa). Only 42% of patients with asthma (primary definition) also met the asthma definition by physician diagnosis and chronic asthma therapy use. CONCLUSION: Among children with early RSV bronchiolitis, hereditary factors (i.e., having a relative with asthma) and RSV bronchiolitis severity were predictors of asthma and atopic disorders at 6 years of age. Of interest, there was poor agreement among the asthma definitions evaluated. Pediatr Pulmonol. 2016;51:1382-1392.
BACKGROUND: We sought to identify predictors of asthma development following severe early childhood RSV bronchiolitis. Different definitions of asthma were also compared. METHODS: This longitudinal, observational study (N = 343) followed patients (<2 years old) from a placebo-controlled trial (N = 979) of montelukast after RSV bronchiolitis to identify clinical, demographic, or biochemical predictors of asthma, atopic disorders, and chronic asthma therapy use at 6 years of age (Clinical Trials Registry Number: NCT01140048). Asthma (primary definition) was based on parental identification of wheeze at 6 AND 12 months before 6 years of age; definitions based on physician diagnosis as well as parental identification of wheeze at 6 OR 12 months (to consider seasonal effect) were also assessed. Post-hoc analyses evaluated agreement among asthma diagnosis criteria. RESULTS: Prevalence of asthma (primary definition by parental identification), asthma (physician diagnosis), atopic disorders, and chronic asthma therapy use (parental identification) was 6.1%, 22.4%, 36.2%, and 14.5%, respectively. Predictors for asthma (primary definition) included male gender, a relative with asthma, and RAST positive for dog dander; for physician diagnosis of asthma, high severity score for RSV bronchiolitis, high respiratory rate, and asthma diagnosis before enrollment. Predictors of atopic disorders included allergic rhinitis before enrollment, a relative with asthma, and the plasma biomarkers IL-5, IL-16, and IL-18. Predictors of chronic asthma therapy use included asthma diagnosis before enrollment and geographic region (Europe and Africa). Only 42% of patients with asthma (primary definition) also met the asthma definition by physician diagnosis and chronic asthma therapy use. CONCLUSION: Among children with early RSV bronchiolitis, hereditary factors (i.e., having a relative with asthma) and RSV bronchiolitis severity were predictors of asthma and atopic disorders at 6 years of age. Of interest, there was poor agreement among the asthma definitions evaluated. Pediatr Pulmonol. 2016;51:1382-1392.
Authors: Le Duc Huy Ta; Gaik Chin Yap; Carina Jing Xuan Tay; Alicia Shi Min Lim; Chiung-Hui Huang; Collins Wenhan Chu; Paola Florez De Sessions; Lynette P Shek; Anne Goh; Hugo P S Van Bever; Oon Hoe Teoh; Jian Yi Soh; Biju Thomas; Mahesh Babu Ramamurthy; Daniel Y T Goh; Christophe Lay; Shu-E Soh; Yiong Huak Chan; Seang-Mei Saw; Kenneth Kwek; Yap-Seng Chong; Keith M Godfrey; Martin Lloyd Hibberd; Bee Wah Lee Journal: J Allergy Clin Immunol Date: 2018-02-13 Impact factor: 10.793
Authors: Cecilia K Andersson; Jua Iwasaki; James Cook; Polly Robinson; Prasad Nagakumar; Sofia Mogren; Louise Fleming; Andrew Bush; Sejal Saglani; Clare M Lloyd Journal: Allergy Date: 2020-07-15 Impact factor: 14.710
Authors: Ioannis N Mammas; Simon B Drysdale; Barbara Rath; Maria Theodoridou; Georgia Papaioannou; Alexia Papatheodoropoulou; Eirini Koutsounaki; Chryssie Koutsaftiki; Eleftheria Kozanidou; Vassilis Achtsidis; Paraskevi Korovessi; George P Chrousos; Demetrios A Spandidos Journal: Int J Mol Med Date: 2020-06-15 Impact factor: 4.101
Authors: Yaneisi Vázquez; Liliana González; Loreani Noguera; Pablo A González; Claudia A Riedel; Pablo Bertrand; Susan M Bueno Journal: Front Immunol Date: 2019-06-04 Impact factor: 7.561
Authors: Diego R Hijano; Luan D Vu; Lawrence M Kauvar; Ralph A Tripp; Fernando P Polack; Stephania A Cormier Journal: Front Immunol Date: 2019-03-26 Impact factor: 7.561